Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, Vancouver.
The purpose of this study was to determine the clinical activity of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Eligible patients had progressive disease within 6 months of receiving docetaxel. Patupilone was administered 10 mg/m(2) i.v. every 3 weeks. The primary end point was the proportion of patients with a confirmed ≥50% prostate-specific antigen (PSA) decline.
Eighty-three patients were enrolled. At baseline, the median time to progression after prior docetaxel was 1.4 months (range 0-5.7). Gastrointestinal serious adverse events occurred in four of the six initial patients leading to a reduction of the starting dose of patupilone to 8 mg/m(2) for subsequent patients. Grade 3-4 toxicity at this dose included diarrhea (22%), fatigue (21%), and anorexia (10%). One patient experienced grade 3-4 hematologic toxicity. A PSA decline of ≥50% occurred in 47% of patients. A partial measurable disease response occurred in 24% of assessable patients. A patient-reported pain response was observed in 59% of assessable patients. Median time to PSA progression was 6.1 months [95% confidence interval (CI) 4.7-8.0] and median overall survival was 11.3 months (95% CI 9.8-15.4).
Patupilone at 8 mg/m(2) was tolerable, had antitumor activity, and was associated with symptomatic improvement in patients previously treated with docetaxel.
Written by:
Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, Ko YJ, Sridhar SS, Weber D, Saad F. Are you the author?
Reference: Ann Oncol. 2011 Jul 16. Epub ahead of print.
doi: 10.1093/annonc/mdr336
PubMed Abstract
PMID: 21765178
UroToday.com Prostate Cancer Section
